Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.
Press releases published on October 15, 2025
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs. The nomination of AMX-883 is underpinned by novel mechanistic …
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report …
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
• TRB-ILD1 granted U.S. Orphan Drug Designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF) • TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) SUNRISE, Fla., Oct. 15, 2025 (GLOBE …
Algernon Pharmaceuticals Completes Name Change to Algernon Health
VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has completed its previously announced …
Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain Platform
- Financing led by Engine Ventures with support from Amplify Partners, Starbloom Capital, Connecticut Innovations, and E1 Ventures - Proceeds to accelerate strategic partnerships and internal CNS development programs to showcase the predictive power of …
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that …
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, …
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois. …
Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund
-- Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline -- Funding underlines urgent global need for novel, resistance-proof antimicrobials JERUSALEM, Israel, October 15, …
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I…
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq …
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 15 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext Compartiment : B Code ISIN : …
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomes More than 40 abstracts …
Vara erhält CE-Zertifizierung als einzige KI für eine unabhängige Zweitbefundung in der Mammographie und expandiert in Europa
BERLIN, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Vara gab heute eine neue CE-Zertifizierung bekannt – die einzige künstliche Intelligenz (KI) auf dem Markt, welche als unabhängige Zweitbefundung sowohl im Screening als auch in der Diagnostik eingesetzt werden …
Vara earns CE mark as the only AI authorized for an independent second read in mammography, and expands in Europe
BERLIN, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Vara announced today it received a new CE certificate for its new breast-imaging AI – the only on the market allowed to operate as an independent second reader for both screening and diagnostic use. It marks the …
EyePoint Announces Pricing of Public Offering
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …